
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical is likely to remain a strong player in the medical device industry, driven by its diverse product portfolio and strategic focus on both global spine and limb reconstruction segments. However, the company's recent streamlining activities and litigation costs may impact its overall financial performance in the short term. In the long term, Orthofix's 2028 target for adjusted EBITDA margin shows potential for growth and solid cash flow generation, leading to a maintained OUTPERFORM rating with a price target of $17 (calculated using 8.5x multiple on 2026 adjusted EBITDA estimate).
Bears say
Orthofix Medical is struggling with headwinds and uncertainties related to the impact of recent Medicare pricing cuts on its bone growth stimulator business. Despite making some organizational changes, the company's preliminary revenue results for Q1/26 suggest that its performance may not meet the expectations of analysts, which could lead to further downward revisions in its guidance for the year. The company showed overall solid performance, but its cash flow and adjusted EBITDA margin guidance for FY/26 and FY/27 was disappointing.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares